Hidenori Machino1,2, Ai Dozen3,4, Mariko Konaka5

  • 1Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, 1-4-1 Nihonbashi, Chuo-ku, Tokyo, 103-0027, Japan. hidenori.machino@riken.jp.

PubMed
概括

这项研究揭示了早期表观遗传变化和转录因子失调在高度血清性卵巢癌 (HGSOC) 的发展. MEK 抑制剂疗法在治疗抗化疗性 HGSOC 的治疗方面显示出有前途.